Frontier IP Group Stock

Frontier IP Group EBITDA per Share

The EBITDA per Share of Frontier IP Group (FIPP.L) as of Aug 13, 2026 is -0.05 GBP. In the previous year, EBITDA per Share was -0.06 GBP — a change of -10.73% (higher).

EBITDA per Share

-0.05GBP

YoY

-10.73%

Last updated:

EBITDA per Share of Frontier IP Group is 2026 -0.05 GBP. EBITDA per Share of Frontier IP Group was 2025 -0.06 GBP. It decreases by -10.73% higher compared to the previous year.
Access this data via the Eulerpool API

Frontier IP Group Stock analysis

What does Frontier IP Group do? The Frontier IP Group PLC is a British company specializing in technology investment and listed on the London Stock Exchange. The company was founded in 2000 and is headquartered in London. Frontier IP invests in promising technology companies and supports them in the development of their products. The business model of Frontier IP is based on investing in promising companies to further develop their technology and business areas. The company has extensive experience in technology development and marketing and works closely with its portfolio companies. Currently, Frontier IP is investing in numerous companies in various sectors such as biotechnology, artificial intelligence, environmental technology, and agricultural technology. The investments range from start-up companies to established companies already present in the market. Each company in which Frontier IP is involved has unique technologies and innovations in the field of research and development, which have a significant impact on their respective markets. The products and services offered by Frontier IP and its portfolio companies include various biotechnological products and procedures, including antibodies, vaccines, and cell therapies. Frontier IP also invests in companies that develop advanced sensor technologies, robotics, and AI systems that can contribute to the automation of various industries. One example is The Vaccine Group. The Vaccine Group was founded in 2003 as a spin-off from the University of Plymouth and is a leading developer of novel human vaccines. The focus is on developing vaccines against infectious diseases classified as special challenges by the World Health Organization (WHO). Another example is Exscientia. Exscientia specializes in applied AI technology to accelerate drug discovery and development. The company has already achieved several groundbreaking successes and collaborates with leading pharmaceutical companies to develop innovative formulations with shorter development times. Frontier IP has also invested in Cambridge Raman Imaging Limited, which has developed an innovative method for high-speed imaging of cells and biological samples. This technology can be used in medical diagnostics or in the development of new drugs. Overall, Frontier IP Group is a significant company in the technology and investment industry. The company specializes in investing in promising technology companies and has extensive expertise in technology development and marketing. Through its investments, Frontier IP has already developed innovative products and services that have a significant impact on various industries and markets and will continue to play an important role in the future. Frontier IP Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Frontier IP Group stock

EBITDA per Share of Frontier IP Group is -0.05 GBP in 2026.

EBITDA per Share of Frontier IP Group changed from -0.06 GBP to -0.05 GBP, representing a -10.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Frontier IP Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — Frontier IP Group

All Key Metrics — Frontier IP Group